Jupiter Topco LLC Invests $10.64 Million in Moderna, Inc. $MRNA

Jupiter Topco LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 151,972 shares of the company’s stock, valued at approximately $10,639,000.

Several other institutional investors and hedge funds have also modified their holdings of MRNA. MUFG Securities EMEA plc bought a new stake in shares of Moderna during the second quarter worth $28,000. Allied Private Wealth LLC acquired a new position in Moderna during the 2nd quarter worth about $30,000. Canton Hathaway LLC bought a new stake in Moderna during the 1st quarter worth about $31,000. EverSource Wealth Advisors LLC grew its holdings in Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after acquiring an additional 801 shares during the last quarter. Finally, Assetmark Inc. increased its position in Moderna by 35.1% in the 1st quarter. Assetmark Inc. now owns 801 shares of the company’s stock valued at $41,000 after acquiring an additional 208 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their personalized mRNA melanoma vaccine, intismeran, combined with Keytruda, met the goals of a Phase 3 study involving 1,137 patients. The treatment reduced the risk of melanoma recurrence and distant spread versus Keytruda alone, strengthening the case for Moderna’s oncology pipeline and the commercial potential of the partnership. Reuters cancer vaccine breakthrough article
• Positive Sentiment: The U.S. FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, targeting the XFG subvariant. The approval preserves access to the seasonal COVID-19 vaccine market, though future demand remains an important uncertainty. Reuters FDA approval article
• Positive Sentiment: Argus upgraded Moderna from “Hold” to “Buy” and assigned a $180 price target, indicating additional potential upside based on the company’s oncology opportunity and recent clinical progress. Argus upgrade article
• Neutral Sentiment: Jim Cramer advised a viewer to hold Moderna after the stock’s sharp rally, reflecting continued optimism about the Phase 3 cancer-vaccine result but also caution following the run-up. Jim Cramer Moderna commentary
• Negative Sentiment: Moderna priced an upsized $2.6 billion offering of zero-coupon convertible senior notes due 2032, increased from the initially proposed $2.0 billion. Proceeds may fund oncology investments and debt repayment, but the larger financing raised concerns about future share dilution and explains much of the selling pressure. Moderna convertible notes offering
• Negative Sentiment: BioNTech’s decision to halt a mid-stage personalized mRNA colorectal-cancer vaccine trial after a review weakened sentiment across the mRNA oncology sector, raising broader questions about the difficulty of translating promising technology into successful cancer treatments. BioNTech colorectal cancer trial article

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 53,336 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. This represents a 3.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the transaction, the insider owned 67,468 shares in the company, valued at $3,373,400. This represents a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 10.80% of the company’s stock.

Moderna Stock Down 3.3%

Shares of NASDAQ:MRNA opened at $137.99 on Friday. Moderna, Inc. has a one year low of $22.28 and a one year high of $176.66. The company has a 50 day moving average of $77.11 and a 200-day moving average of $59.73. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The stock has a market cap of $55.09 billion, a price-to-earnings ratio of -17.27 and a beta of 0.91.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period in the prior year, the business posted ($2.13) earnings per share. Moderna’s revenue was up 2.1% compared to the same quarter last year. On average, sell-side analysts forecast that Moderna, Inc. will post -6.11 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Loop Capital set a $135.00 target price on shares of Moderna in a research report on Wednesday, August 19th. Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a report on Tuesday. Piper Sandler restated an “overweight” rating on shares of Moderna in a research report on Monday, August 3rd. Bank of America raised Moderna from an “underperform” rating to a “neutral” rating in a report on Wednesday, August 19th. Finally, Argus upgraded Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Friday. Seven analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $80.53.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.